# EMulate Therapeutics

Revolutionary Transformation of Medicine with BioElectromagnetic Technology

- Canonical URL: https://wefunder.com/emulatetx
- Entity ID: wefunder:company:182421
- Last updated: 2026-06-05T05:01:16Z
- Generated at: 2026-06-06T02:13:05Z

## Quick facts
- We have made our very limited public round now available to outside investors.

## Active fundraises
- wefunder:fundraise:142738: 4(a)(6) successful (USD)
- wefunder:fundraise:142737: 4(a)(6) successful (USD)

## Story
Imagine a world where cancer patients, such as children with brain tumors, could receive life-saving treatment without toxic chemotherapy. Where chronic pain sufferers could find relief without addictive opioids. Where mental health conditions could be managed with no significant observed side effects. This isn't science fiction, this is happening now at EMulate Therapeutics.EMulate has solved one of medicine's most elusive challenges: delivering therapeutic benefits without physical drugs. Here's how it works in simple terms:Every molecule, including medicines, creates unique electromagnetic "fingerprints" as it moves. Think of it like each drug having its own song. EMulate's scientists use ultra-sensitive equipment to record these molecular songs, then play them back to patients using safe, low-energy radio waves through a simple wearable device.The result? Your body responds as if it received the actual medication, but without any chemicals entering your system. No toxicity. No observed significant side effects. Just therapeutic benefits.ulRFE® Technology A proprietary mechanism for the non-toxic, non-invasive, non-ionizing and effective treatment of cancer, pain, mental health and general wellness.Pediatric Brain Cancer: A Breakthrough Where None ExistedEMulate's most advanced program targets Diffuse Midline Glioma (DMG), including Diffuse Intrinsic Pontine Glioma (DIPG), devastating childhood brain cancers that have seen no meaningful treatment advances in decades.The Drug They Emulate: Paclitaxel (Taxol), a powerful chemotherapy drug that works by disrupting cancer cell division. While highly effective against many cancers, paclitaxel cannot cross the blood-brain barrier, making it useless for brain tumors until now.The science behind this success: EMulate's “song” of paclitaxel, like the drug itself, promotes tubulin polymerization (the process that slows cancer cell division), but delivers this effect directly to brain tumors, unlike drugs, which would need to (but cannot) cross the blood-brain barrier. Adult Brain Cancer (Glioblastoma): First Real Progress in DecadesFor glioblastoma multiforme (GBM), the most common and aggressive adult brain cancer, EMulate's Voyager system has shown remarkable resultExpanding Oncology ApplicationsBeyond brain cancers, EMulate has demonstrated responses in over 20 different tumor types through veterinary canine studies, including:Complete responses in osteosarcoma, lymphomas, and carcinomasPartial responses in melanoma, fibrosarcoma, and mammary tumorsOver 300 pets treated with naturally occurring cancersResponses observed as early as 14 days with therapyRevolutionizing Psychiatric TreatmentEMulate's mental health program leverages the therapeutic potential of psychedelic compounds while reducing or eliminating many risks and drug-related challenges. The company has successfully emulated the effects of several breakthrough mental health medications.The Drugs They Emulate:DOI (2,5-Dimethoxy-4-iodoamphetamine): A research psychedelic used as the "gold standard" in psychiatric studiesKetamine: FDA-approved for treatment-resistant depressionMDMA: which is currently in Phase 3 trials for PTSDPsilocybin: Breakthrough therapy designation for depressionCBD and THC: in active research for depression and anxietyBreaking the Addiction CycleWith the opioid crisis claiming over 100,000 lives annually in the US alone, EMulate's pain management platform offers hope for non-addictive, effective pain relief.The Drugs We Emulate:Fentanyl: The most powerful opioid painkillerCBD (Cannabidiol): Natural anti-inflammatory compoundNSAIDs: Including naproxen and indomethacinHydromorphone: Another potent opioidInflammatory Pain Model:Fentanyl signal: 65% pain reduction (p≤0.01)CBD signal: 65% pain reduction (p≤0.01)Both outperformed indomethacin (standard anti-inflammatory)Neuropathic Pain Model:Fentanyl signal: 82% pain reduction (p≤0.01)CBD signal: 70% pain reduction (p≤0.01)Naproxen signal: 79% pain reduction (p≤0.01)Post-Surgical Pain Model:Fentanyl signal: 70% pain reduction (p=0.01)Comparable to high-dose morphine without addiction riskHuman Case Studies:Five military veterans with chronic pain conditions treated at a VA medical center:38% average reduction in pain scores (Visual Analog Scale)Pain scores dropped from 8/10 to 5/10 averageEffects observed within 15-30 minutesAll patients had previously failed traditional pain managementEMulate's pain device combines signals from opioids, NSAIDs, and CBD to create multi-modal pain relief potentially without:AddictionLiver toxicityGastrointestinal side effectsRespiratory depressionDrug interactionsHow BioElectromagnetic Technology WorksEMulate's technology operates on fundamental principles of biophysics. Non-covalent molecular interactions, the same forces that allow drugs to produce a biological response, involve electromagnetic fields. With these fields, EMulate triggers the same biological cascades as physical drugs.Safety Profile Across All ProgramsWith over 165 human patients treated across oncology trials, millions of hours of consumer exposure through Hapbee, and extensive animal testing:Zero serious adverse events attributable to ulRFE technologyNo thermal effects (non-heating)No ionizing radiation (low energy levels)No observed tissue damage or cellular toxicityThis isn't just about one disease. EMulate's platform can theoretically recreate the effects of any non-covalent drug molecule. Our patented ultra-low radio frequency energy (ulRFE®) technology records and reproduces specific electromagnetic patterns associated with familiar compounds, then plays those patterns through lightweight wearables for consumers. The result is an on-demand, drug-free way to nudge sleep, focus, calm, or energy with instant on/off control drug-free.The Hapbee Neckband targets daytime performance (Focus, Energy, Calm, Relax) while the Hapbee Sleep Pad lives under your pillow for nighttime use (Deep Sleep, Wind Down, Wake Up). Both pair to an app with a growing library of “signal blends,” letting users choose how they want to feel throughout the day and night. Led by CEO Chris Rivera, who previously built and sold Hyperion Therapeutics for $1.1 billion, EMulate's team combines decades of biotech success with cutting-edge scientific innovation. The board includes veterans from Microsoft, Bristol Myers Squibb, and multiple successful biotech ventures.Near-Term Revenue Catalysts2027: Projected commercial launch for pediatric brain cancer (DMG/DIPG)$100M+ market opportunity within 3 years of launch (not guaranteed)Multiple Phase 1 trials starting in 2025 for pain and mental health Ongoing License royalties from Hapbee TechnologiesMassive Market PotentialBrain Cancer: $4.8B by 2030Mental Health: $567B by 2032Pain Management: $114B by 2032Total addressable market exceeds $700 billionProven Business ModelRevenues through licensing deals with Teijin Pharma (Japan) and Sayre Therapeutics (India)15 issued patents protecting the technologyHapbee already commercializing consumer wearable productsCapital EfficiencyUnlike traditional drug development requiring billions in investment:New treatments developed in less than 12 monthsUnder $500,000 from concept to clinical readinessNo need to invent new molecules, just record existing onesEMulate Therapeutics isn't just another biotech company, it's pioneering an entirely new category of medicine. With near-term commercialization, multiple shots on goal, and a technology platform that could transform how we treat disease, this is a rare opportunity to invest in a true medical breakthrough.The company is actively raising capital to:Complete FDA approval and launch DMG/DIPG treatmentAdvance multiple Phase 1 trials in pain and mental healthGenerate additional data for other tumor typesExpand commercial partnerships globallyBe Part of the FutureNow, with commercial launch imminent following FDA approval, the company is positioned for explosive growth.This is your chance to invest in a company that could fundamentally change medicine, making treatments safer, more accessible, and more effective for millions of patients worldwide.

## FAQ
1. **SynergyMed raised on Wefunder, and had a similar solution to the problem of cancer treatment. Their value cap was only 16M, which was much more appealing to me. Their approach was also to break into the Vet market first, to prove their technology. To generate revenue, and pote...**
   - Jesse, we looked into the vet cancer market. It is very limited for novel technologies based on our market research. DIPG is a very rare, terminal, pediatric brain cancer. A relative short FDA path. Pain management is also a expeditious path to revenue. We are planning a direct Nasdaq listing this year, so your investment will be liquid. Thanks for your consideration. Best

## Team
- Chris Rivera (President & CEO)
- Kyle Kingma (Chief Financial Officer)
- Steven Pope (Sr. VP, General Counsel & Secretary)
- Xavier Andres Figueroa (SVP, Pre-Clinical Development)

## Q&A
- Q: SynergyMed raised on Wefunder, and had a similar solution to the problem of cancer treatment. Their value cap was only 16M, which was much more appealing to me. Their approach was also to break into the Vet market first, to prove their technology. To generate revenue, and potentially profit, sooner rather than later, I think that's a smart strategy. Do you have similar plans? I love the idea, conceptually, but have you done a market analysis on specific diseases can be treated, especially in the vet industry?
  - A: Jesse, we looked into the vet cancer market. It is very limited for novel technologies based on our market research. DIPG is a very rare, terminal, pediatric brain cancer. A relative short FDA path. Pain management is also a expeditious path to revenue. We are planning a direct Nasdaq listing this year, so your investment will be liquid. Thanks for your consideration. Best
- Q: Hi Team: This sounds like a great idea!!! 1) What is your target for USA sales? Have you started the process of FDA approval? Are their regulatory issues in India and China to sell this device to treat diseases and what is the status of those approvals? 2) Also, my understanding is that most drugs work by attaching to receptors in the body. How can these radio wave emulate that? Where can I download some technical papers? 3) Can you provide a bibliography of clinical results papers. Thank you, Mark
- Q: Hey, ive been trying and I have not been able to reach anyone from the team... can someone please be in touch with me. Thanks...
- Q: How do we get the shares once you go public, and is there any lockup period?
- Q: What is your current revenue?
- Q: I'm in; main two reasons: a non-drug, non-invasive technology delivered thru a therapeutic platform that can address unmet medical needs is a major disruptor
- Q: hello, do you have a mechanism through your technology that understand the current emotional state of an individual and match with the selected vocal or instrumental music seamlessly. At the end of the session, it will give a summary of whether listening to that music helped an individual in 3 categories -> helped , not helped , neutral.